<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04869436</url>
  </required_header>
  <id_info>
    <org_study_id>3618</org_study_id>
    <nct_id>NCT04869436</nct_id>
  </id_info>
  <brief_title>Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis</brief_title>
  <official_title>The 'Real World' Olfactory Outcomes Treating Nasal Polyposis With Dupilumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mount Sinai Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to investigate the olfactory TDI score (Threshold, Discrimination,&#xD;
      Identification) using the Sniffin' sticks test for patients with chronic rhinosinusitis with&#xD;
      nasal polyps (CRSwNP) on dupilumab. Twenty-seven adult patients will be followed up during&#xD;
      the treatment with dupilumab on three visits to the Otolaryngology Clinic (Baseline, 3 months&#xD;
      and 6 months).&#xD;
&#xD;
      The primary endpoint will be the TDI score. Nasal polyp score, Quality of Olfactory Disorders&#xD;
      - negative symptoms (QOD-NS symptom scores), SNOT-22 will be secondary endpoints.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single group 6 months treatment with Dupilumab.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the Smell Threshold, Identification and Discrimination (TDI score) at week 12 and week 24.</measure>
    <time_frame>Baseline, 12 weeks and 24 weeks.</time_frame>
    <description>The Sniffin' Sticks test involves testing odor for threshold and discrimination whilst blind folded and secondly odor identification. The sum of four odors responses ranges from 0-16. The sum of total score from odor Threshold, Discrimination and Identification (TDI) is a maximum of 48 points. The total score is graded as; normosmia equals or over 30.5 points, hyposmia 16.5-30 points and anosmia less than 16.5 points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Nasal Polyps score at weeks 12 and 24.</measure>
    <time_frame>Baseline, 12 weeks and 24 weeks.</time_frame>
    <description>Nasal Polyps score is the sum of the right and left nostril scores (endoscopic assessment). Total score ranges from 0 (no polyps) to 8 (large polyps on for each nostril [4+4] ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Sino-nasal outcome test- 22 (SNOT-22) at weeks 12 and 24.</measure>
    <time_frame>Baseline, 12 weeks and 24 weeks.</time_frame>
    <description>SNOT-22 is a validated questionnaire to assess the impact of chronic rhinosinusitis on patients' quality of life. Patient grades the impact of 22 potential symptoms in their life, by choosing from 0 [no problem] to 5 [problem as bad as it can be]. Highest possible score is 10 (worst quality of life); minimal clinically important change ≥ 8.90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the QOD-NS at weeks 12 and 24.</measure>
    <time_frame>Baseline, 12 weeks and 24 weeks.</time_frame>
    <description>Quality of Olfactory Disorders - negative symptoms (questionnaire)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Chronic Rhinosinusitis With Nasal Polyps</condition>
  <condition>Olfactory Disorder</condition>
  <arm_group>
    <arm_group_label>Dupilumab group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with CRSwNP will have an initial dose of 600 mg of dupilumab, and 5 additional doses of 300mg every 4 weeks for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]</intervention_name>
    <description>Dupilumab will be administered subcutaneously for 6 months (1 initial 600mg dose + 5 300mg doses every 4 weeks)</description>
    <arm_group_label>Dupilumab group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients older than 18 years old&#xD;
&#xD;
          -  Chronic rhinosinusitis with Nasal Polyps&#xD;
&#xD;
          -  Olfactory loss&#xD;
&#xD;
          -  Clinical indication for treatment with Dupilumab&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with olfactory loss from other causes such as:&#xD;
&#xD;
          -  Sinonasal malignancies&#xD;
&#xD;
          -  Trauma&#xD;
&#xD;
          -  Idiopathic olfactory loss&#xD;
&#xD;
          -  Use of cocaine&#xD;
&#xD;
          -  COVID-19 related olfactory loss&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leigh J Sowerby, MD, FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Joseph's Hospital London, ON, Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Taciano Rocha, PhD</last_name>
    <phone>+15196466100</phone>
    <phone_ext>61125</phone_ext>
    <email>taciano.rocha@sjhc.london.on.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Joseph's Health Care</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leigh J Sowerby</last_name>
    </contact>
    <investigator>
      <last_name>Leigh J Sowerby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Rotenberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Leigh Sowerby</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasal Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to make IPD available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

